comparemela.com
Home
Live Updates
Anokion SA: Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease : comparemela.com
Anokion SA: Anokion Announces New Clinical Data from the Phase 1b/2 ACeD-it Trial Supporting KAN-101 as a Potential Disease-Modifying Treatment for Celiac Disease
Two Global Phase 2 Clinical Trials, the Phase 2 portion of ACeD-it and Phase 2a SynCeD Studies, are Ongoing in Individuals with Celiac Disease New Data Presented During Digestive Disease Week® 2024
Related Keywords
Switzerland ,
Swiss ,
Chris Brinzey ,
Deborah Geraghty ,
,
Two Global Phase ,
Synced Studies ,
Data Presented During Digestive Disease Week ,
Potential Treatment ,
Immune Tolerance ,
Higher Dose Levels ,
Novel Immune Tolerance Therapy ,
Celiac Disease ,
Digestive Disease Week ,
Fast Track Designation ,
Ihr Portfolio ,
comparemela.com © 2020. All Rights Reserved.